Skip to main content

Table 2 Somatic mutation genotyping results by oestrogen receptor and progesterone receptor status and treatment arm

From: Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies

   PIK3CA mutated ERBB mutated PIK3CA/ERBB mutateda
Tumour group Total no. of tumours No. of tumours (%) No. of tumours (%) No. of tumours (%)
ER status
 Negative 29 8 (27.6) 1 (3.4) 8 (27.6)
 Positive 45 10 (22.2) 7 (15.6) 15 (33.3)
PR status
 Negative 43 9 (20.9) 5 (11.6) 14 (32.6)
 Positive 31 8 (25.8) 3 (9.7) 9 (29)
Treatment arm
 TCL 10 3 (30) 2 (20) 3 (30)
 TCH 32 9 (28.1) 2 (6.3) 10 (31.3)
 TCHL 32 6 (18.8) 4 (12.5) 10 (31.3)
  1. Abbreviations: ER Oestrogen receptor, PR Progesterone receptor, TCH Docetaxel, carboplatin, and trastuzumab, TCHL Docetaxel, carboplatin, trastuzumab, lapatinib, TCL Docetaxel, carboplatin, lapatinib
  2. Association of PIK3CA mutations, ERBB family mutations and combined PIK3CA/ERBB family mutations with ER and PR status. The mutation frequency in each treatment arm is also shown
  3. aThese numbers/percentages may not be a sum of PIK3CA and ERBB mutated because of mutation overlap